Cargando…

A tale of two drug targets: the evolutionary history of BACE1 and BACE2

The beta amyloid (APP) cleaving enzyme (BACE1) has been a drug target for Alzheimer's Disease (AD) since 1999 with lead inhibitors now entering clinical trials. In 2011, the paralog, BACE2, became a new target for type II diabetes (T2DM) having been identified as a TMEM27 secretase regulating p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Southan, Christopher, Hancock, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865767/ https://www.ncbi.nlm.nih.gov/pubmed/24381583 http://dx.doi.org/10.3389/fgene.2013.00293

Ejemplares similares

Amino Acid Sequence and Structural Comparison of BACE1 and BACE2 Using Evolutionary Trace Method
por: Mirsafian, Hoda, et al.
Publicado: (2014)

RCAN1 Inhibits BACE2 Turnover by Attenuating Proteasome-Mediated BACE2 Degradation
por: Qiu, Kaixin, et al.
Publicado: (2020)

Is It the Twilight of BACE1 Inhibitors?
por: Hrabinova, Martina, et al.
Publicado: (2021)

Sorting nexin 12 interacts with BACE1 and regulates BACE1-mediated APP processing
por: Zhao, Yonghao, et al.
Publicado: (2012)

The effect of BACE1-AS on β-amyloid generation by regulating BACE1 mRNA expression
por: Li, Fan, et al.
Publicado: (2019)

BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats
por: Weber, Martin, et al.
Publicado: (2017)

Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice
por: Shimshek, Derya R., et al.
Publicado: (2016)

Developing BACE-1 inhibitors for FXS
por: Westmark, Cara J., et al.
Publicado: (2013)

Early elevation of BACE1 in dementia
por: Cervellati, Carlo, et al.
Publicado: (2021)

Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors
por: Brodney, Michael A., et al.
Publicado: (2015)

Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome()
por: Mok, Kin Y., et al.
Publicado: (2014)

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
por: Vassar, Robert
Publicado: (2014)

BACE1 and SCD1 are associated with neurodegeneration
por: Bedoya-Guzmán, Ferley A., et al.
Publicado: (2023)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
por: Maia, Miguel A., et al.
Publicado: (2019)

BACE1: from biomarker to Alzheimer’s disease therapeutical target
por: Cervellati, Carlo, et al.
Publicado: (2021)

PS1 Affects the Pathology of Alzheimer’s Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus
por: Li, Nuomin, et al.
Publicado: (2022)

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants
por: Timmers, Maarten, et al.
Publicado: (2017)

The BACE1-generated C-terminal fragment of the neural cell adhesion molecule 2 (NCAM2) promotes BACE1 targeting to Rab11-positive endosomes
por: Keable, Ryan, et al.
Publicado: (2022)

Regulation of dynamic BACE1 trafficking in neurons
por: Buggia-Prévot, Virginie, et al.
Publicado: (2013)

Evaluation of BACE1 Silencing in Cellular Models
por: Sierant, Malgorzata, et al.
Publicado: (2009)

Development and Structural Modification of BACE1 Inhibitors
por: Gu, Ting, et al.
Publicado: (2016)

Role of BACE1 in Alzheimer’s synaptic function
por: Das, Brati, et al.
Publicado: (2017)

Expression of BACE1 in the Rat Carotid Body
por: Li, Chaohong, et al.
Publicado: (2020)

Attenuated ability of BACE1 to cleave the amyloid precursor protein via silencing long noncoding RNA BACE1-AS expression
por: LIU, TE, et al.
Publicado: (2014)

pHluorin-BACE1-mCherry Acts as a Reporter for the Intracellular Distribution of Active BACE1 In Vitro and In Vivo
por: Zhao, Lu, et al.
Publicado: (2019)

Two novel DNA motifs are essential for BACE1 gene transcription
por: Xiang, Yan, et al.
Publicado: (2014)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
por: Coimbra, Judite R. M., et al.
Publicado: (2018)

Palmitoylated APP Forms Dimers, Cleaved by BACE1
por: Bhattacharyya, Raja, et al.
Publicado: (2016)

Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer’s Disease Therapy
por: Ugbaja, Samuel C., et al.
Publicado: (2022)

The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007)

Multifunctional Donepezil Analogues as Cholinesterase and BACE1 Inhibitors
por: Green, Keith D., et al.
Publicado: (2018)

Post-Translational Modifications of BACE1 in Alzheimer's Disease
por: Wen, Wen, et al.
Publicado: (2022)

Surface Trafficking of APP and BACE in Live Cells
por: Bauereiss, Anna, et al.
Publicado: (2015)

Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs
por: Yan, Riqiang
Publicado: (2016)

BACE1 activity regulates cell surface contactin-2 levels
por: Gautam, Vivek, et al.
Publicado: (2014)

MicroRNA-149 is downregulated in Alzheimer’s disease and inhibits β-amyloid accumulation and ameliorates neuronal viability through targeting BACE1
por: Du, Wenyan, et al.
Publicado: (2021)

The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer’s Disease
por: Cole, S.L, et al.
Publicado: (2007)

The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease
por: Vassar, Robert, et al.
Publicado: (2011)

BACE1-Dependent Neuregulin-1 Signaling: An Implication for Schizophrenia
por: Zhang, Zhengrong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c8jmn256u5hibg0qhi8osf2pbc